Welcome to our dedicated page for INSMED SEC filings (Ticker: INSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Insmed Incorporated filings document formal disclosures for its commercial biopharmaceutical portfolio and respiratory and inflammatory pipeline. Recent Form 8-K reports furnish financial results, investor presentations, Regulation FD materials, clinical-study updates for ARIKAYCE and brensocatib, regulatory approval announcements for BRINSUPRI, and portfolio additions such as INS1148.
The company’s proxy materials describe board elections, executive compensation, equity awards, shareholder voting matters and governance practices. Other current reports document compensatory arrangements, director-transition disclosures, exhibits and Inline XBRL cover-page data tied to Insmed’s Nasdaq-listed common stock.
Insmed Incorporated reported strong growth for the fourth quarter and full year 2025 while remaining deeply loss-making and setting ambitious 2026 revenue goals. Total revenue reached $606.4 million in 2025, up from $363.7 million, driven by the U.S. launch of BRINSUPRI and continued ARIKAYCE expansion.
BRINSUPRI generated $144.6 million in Q4 and $172.7 million for 2025, while ARIKAYCE delivered $119.2 million in Q4 and $433.8 million for the year, representing 19% annual growth. Despite this, Insmed posted a 2025 net loss of $1.28 billion, as operating expenses rose to $1.85 billion. The company ended 2025 with approximately $1.4 billion in cash, cash equivalents, and marketable securities and guides for at least $1 billion in 2026 BRINSUPRI revenue and $450–$470 million from ARIKAYCE. Insmed also highlighted Orphan Drug Designation for TPIP in pulmonary arterial hypertension and ongoing late-stage studies. Separately, director David W.J. McGirr will not stand for re-election at the 2026 annual meeting but will continue serving until then.
INSMED Inc. director David W. J. McGirr reported a bona fide gift transfer of 53,400 shares of common stock on February 9, 2026. The filing shows 53,400 shares moved from his direct holdings to indirect ownership through a family trust, leaving 44,323 shares held directly and 53,400 shares held indirectly.
INSMED Inc.’s Chair and CEO William Lewis reported option exercises and share sales on common stock. On February 9, 2026, he exercised stock options for 4,440 shares at $17.16 and 6,259 shares at $30.46 per share, converting them into common stock. The same day, he sold 4,888 shares at a weighted average price of $147.17, 7,221 shares at $148.02, and 1,287 shares at $148.83, under a Rule 10b5-1 trading plan adopted on September 4, 2025. After these transactions, he directly owned 301,185 common shares and had indirect ownership of 233,924 shares through the Katie Procter Dynasty Trust and 50,500 shares through the William Lewis Family Legacy Trust.
William Lewis filed a Rule 144 notice to sell 13396 Insmed common shares. The filing lists Merrill Lynch as broker, with the shares to be sold on NASDAQ and an aggregate market value of 1979774. It notes 213273469 common shares outstanding.
The shares to be sold were acquired through stock plan activity, including 10699 shares on 02/09/2026 and 2697 shares on 02/01/2026. The notice also details several prior open-market sales over the past three months with disclosed share counts and gross proceeds.
Insmed Inc.’s Chief Medical Officer, Martina Flammer, M.D., reported a planned stock sale. On 02/05/2026 she sold 869 shares of Insmed common stock at $152.44 per share in a transaction coded as a sale. After this trade, she beneficially owned 83,243 shares directly.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan that she adopted on February 27, 2025. Such plans allow insiders to schedule trades in advance, helping separate routine portfolio moves from day-to-day corporate developments.
A holder of common stock in a NASDAQ‑listed company has filed a Form 144 notice to sell 869 shares through Merrill Lynch, with an aggregate market value of $132,462. The filing states that 213,273,469 shares of this class were outstanding and lists an approximate sale date of February 5, 2026.
The securities to be sold were acquired on February 1, 2026 via stock plan activity from the issuer. The person filing, identified in recent sales as Martina Flammer, also sold multiple blocks of common shares between November 11, 2025 and February 3, 2026, with individual trades ranging from hundreds to tens of thousands of shares.
INSMED Inc.'s Chief Operating Officer Roger Adsett reported a routine sale of company stock in connection with equity compensation. On February 3, 2026, he sold 791 shares of common stock at a price of $156.17 per share. A footnote explains that the shares were sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees, rather than as a discretionary open-market sale. After this transaction, Adsett beneficially owned 106,810 shares of INSMED common stock directly.
Insmed Inc.'s Chief Financial Officer, Sara Bonstein, reported a small share sale under a Form 4 filing. On 02/03/2026, she sold 748 shares of Insmed common stock at a price of $156.34 per share. According to the filing, these shares were sold to satisfy tax withholding obligations tied to the vesting of Restricted Stock Units and to cover related broker fees, rather than as a discretionary sale. After this transaction, Bonstein beneficially owned 79,758 shares of Insmed common stock directly.
Insmed Inc. Chair and CEO William Lewis reported a routine share sale linked to tax withholding. On February 3, 2026, he sold 3,009 shares of common stock at $156.34 per share to satisfy tax obligations from vested restricted stock units and related broker fees. After this sale, he directly owned 303,882 shares of Insmed common stock. In addition, he had indirect beneficial ownership of 233,924 shares through the Katie Procter Dynasty Trust and 50,500 shares through the William Lewis Family Legacy Trust.
INSMED Inc's Chief Legal Officer reports a routine share sale related to equity compensation. On 02/03/2026, Michael Alexander Smith sold 640 shares of INSMED common stock at $156.27 per share. The filing explains the shares were sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. After this transaction, he directly beneficially owned 56,397 shares of common stock.